SecBot SecBot
Biotech Drug Report Generated Aug 21, 2026

ACR-2316

ACRV·Acrivon Therapeutics, Inc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Early clinical (Phase 1-type); no Phase 2/3 trial yet
Time to market
Unknown, likely several years away: the drug is in early clinical (Phase 1-type) testing as of mid-2026, with no registrational trial started.
Why 3/10
No hard, dated binary catalyst for ACR-2316 is scheduled in the next ~12 months, only scientific-conference data updates on its ongoing early clinical (Phase 1-type) program, and the company's dated 2H 2026 catalyst belongs to lead asset ACR-368's Phase 2b interim, so ACR-2316 rates low (3) on the impact scale.
Actionable Insight NEUTRAL

ACR-2316 is a longer-dated option inside Acrivon: watch for quantitative response/tolerability numbers from its ongoing Phase 1 dose escalation at oncology congresses, since the July 2026 AACR D3 disclosure contained no patient counts or response rates. Note that near-term ACRV share-price action is driven by the ACR-368 Phase 2b prespecified interim analysis and all-comer serous endometrial cancer data guided for 2H 2026, not by ACR-2316, so any trade thesis should center on ACR-368 with ACR-2316 as upside optionality.

Price Chart

Loading chart...

Executive Summary

ACR-2316 is Acrivon Therapeutics' (Nasdaq: ACRV) investigational dual WEE1/PKMYT1 inhibitor, described by the company as a potential first-in-class clinical-stage drug designed via its proprietary AP3 platform. Early data through mid-2026 show initial clinical activity (lung cancer) and early partial responses across multiple biomarker-predicted tumor types with favorable tolerability, though no quantitative efficacy figures have been released. It is a secondary program behind the company's lead asset ACR-368, and no regulatory binary for ACR-2316 is scheduled.

How It Works

Cancer cells with DNA damage normally pause their division so they can repair themselves, using two "checkpoint" proteins called WEE1 and PKMYT1. ACR-2316 blocks both proteins at once, forcing damaged cancer cells to divide prematurely and die. Acrivon says the drug was rationally designed with its AP3 (phosphoproteomics) platform to be potent on its own and to have a better safety window ("superior therapeutic index") than earlier WEE1-type drugs.

Trial Status

ACR-2316 is in an early clinical (dose-escalation-type) program. The July 21, 2026 AACR D3 conference press release highlighted "early clinical data" with early partial responses across multiple AP3-predicted tumor types and a favorable tolerability profile, without disclosing quantitative response rates or patient numbers. The Q4/FY2025 results release (March 19, 2026) cited "initial clinical activity" for ACR-2316 in lung cancer, and April 2026 AACR posters showed preclinical synergy with immune checkpoint inhibitors and ADC payloads.

The Two-Sided Case

▲ Bull Case5
Potential first-in-class dual WEE1/PKMYT1 inhibitor, rationally designed with Acrivon's AP3 platform for potent single-agent activity and a 'superior therapeutic index' (July 21, 2026 AACR D3 release).
Early clinical data show partial responses across multiple AP3-predicted tumor types with a favorable tolerability profile, plus 'initial clinical activity' in lung cancer per the Q4/FY2025 results release (March 19, 2026).
Preclinical data (AACR, April 17, 2026) show strong synergy of ACR-2316 with immune checkpoint inhibitors (anti-PD-L1), suggesting broad combination development optionality.
Parent company has cash runway into Q2 2027 and a 13F-backed institutional base (Vanguard, Wellington, Renaissance, Two Sigma held ACRV in Q2 2026), with 13 of 14 tracked analyst ratings at Buy/Strong Buy.
At $2.20 the stock trades well below the $11.50 analyst mean price target (implied upside ~377% per local consensus), though that target reflects the whole pipeline, not ACR-2316 alone.
▼ Bear Case5
Very early stage: the July 2026 AACR D3 disclosure gave no quantitative response rates or patient numbers, so the clinical signal is unproven and Phase 1 data frequently fails to replicate in later trials.
No scheduled hard catalyst for ACR-2316 in the next ~12 months; ACRV's dated near-term event is the ACR-368 Phase 2b interim analysis in 2H 2026 (Aug 12, 2026 release), so this drug alone won't drive a major move.
Crowded and competitive WEE1 space: Zentalis' azenosertib is late-stage and just raised ~$92.6M gross (Aug 2026), and Aprea's WEE1 inhibitor APR-1051 is in Phase 1 with partial responses reported, first-in-class is not the same as only-in-class.
Micro-cap risk profile: ACRV ~$2.20 (52-week range $1.27–$3.56), no insider open-market buying in the last 90 days (only small tax-withholding sales), and short interest ~3.17% of estimated shares outstanding as of the July 31, 2026 settlement.
Company-level reliance on a single near-term binary: if ACR-368's 2H 2026 Phase 2b readout disappoints, financing/dilution risk rises for the whole pipeline including ACR-2316.

Upcoming Catalysts

  • Scientific-conference data updates on ACR-2316 Phase 1 dose escalation (no fixed date published; prior updates at AACR/AACR D3).
  • Company-level, not drug-specific: ACR-368 Phase 2b prespecified interim analysis and all-comer serous endometrial cancer data, guided for 2H 2026 (Aug 12, 2026 release).
  • Company-level: planned FDA IND submission for ACR-6840 in Q4 2026 (SEC-extracted catalyst, Mar 19, 2026).
  • Next quarterly financial results (Q3 2026, typically ~November), which typically restate pipeline timing.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Acrivon Therapeutics, Inc Press Release ACRV ·Originating report

Sources · 8

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 globenewswire.com5 globenewswire.com6 sec.gov7 sec.gov8 sec.gov